Weaver C. Barksdale & Associates Inc. reduce stakes in Pfizer Inc. (NYSE:PFE)

Weaver C. Barksdale & Associates Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,652 shares of the biopharmaceutical company’s stock after selling 802 shares during the quarter. Holdings held by Weaver C. Barksdale & Associates Inc. in Pfizer were worth $942,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Cantor Fitzgerald Investment Advisors LP purchased a new position in Pfizer in the 4th quarter valued at $16,166,000. LGT Group Foundation raised its stake in shares of Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after acquiring an additional 18,274 shares in the last quarter. ORG Partners LLC raised its stake in shares of Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 44,458 shares during the last quarter. Kempner Capital Management Inc. purchased a new position in Pfizer in the first quarter worth about $2,439,000. Finally, Leo Wealth LLC purchased a new position in Pfizer in the 4th quarter valued at about $2,171,000. Hedge funds and other institutional investors own 68.36% of the company’s shares.

Pfizer stock fell 0.3%

Shares of Pfizer stock opened at $29.67 on Friday. The company has a market cap of $168.13 billion, a PE ratio of -494.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60, and a current ratio of 0.86. Pfizer Inc. it has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The firm has a 50-day moving average price of $29.35 and a 200-day moving average price of $28.20.

Pfizer (NYSE:PFE – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. In the same period last year, the firm posted earnings of $0.67 per share. The company’s revenue rose 2.1% year over year. Research analysts expect that Pfizer Inc. to post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26. This represents an annualized dividend of $1.68 and a dividend yield of 5.66%. Pfizer’s dividend payout ratio is currently -2,799.53%.

The Wall Street analyst weighs in

PFE has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Daiwa America upgraded Pfizer from a “moderate-buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group lifted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat , Pfizer has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Read the latest stock report on Pfizer

Pfizer profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United States, Europe and internationally. The company offers drugs and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine and women’s health under the brands Eliquis, Nurtec ODT/Vydura, Zavzpret and Premarin; infectious diseases with unmet medical needs under the family brands Prevnar, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; and the prevention and treatment of COVID-19 and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured stories

Want to see what other hedge funds own PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Pfizer Inc. (NYSE:PFE – Free Report).

Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.